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The use of contrast agents during echocardiography is not 
new, and substantial qualitative evaluations with this ap•
proach have been reported (1-4), Recently, a lACC seminar 
(5) dealt with an extension of the contrast echo technique 
to the measurement of the size of underperfused myocar•
dium and potentially to quantitation of myocardial blood 
flow. In the initial experimental studies (6,7), intracoronary 
or aortic root injection of a small amount of contrast agent, 
such as an agitated saline-Renografin mixture, enhanced 
two-dimensional echocardiographic images to a degree, al•
lowing quantitative delineation of acute ischemic perfusion 
defects in short-axis left ventricular sections. Additional 
studies (8) demonstrated apparent safety and validated this 
technique in the dog. Refinements of the technique applied 
computer assist and digital subtraction methods (9, 10), and 
problems in defining the myocardial contrast echoes have 
been examined (11). 
Delineation and quantitation of myocardial ischemia 
or infarcted zone. The delineation of the ischemic risk 
zone in multiple cross sections has been logically applied 
by Kaul et al. (12) in this issue of the Journal. These authors 
satisfactorily correlated in dogs the echo contrast-derived 
ischemic risk region with various modes of regional dys•
function analysis, based on two-dimensional measurements 
obtained just before the administration of echo contrast agents. 
In vivo real time quantitation of the risk zone is of substantial 
interest, and can serve to normalize measurements of irre•
versible ischemic damage when coronary anatomy and col-
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lateral circulation vary substantially. Kaul et al. conclude 
that the myocardial contrast echo method will be a useful 
complement to current echocardiographic measurements of 
ischemic function. There is a need, however, to provide a 
perspective on the current state of the art and recognize 
problems that might be encountered in future applications. 
Reviewing the data of Kaul et al. obtained during left 
anterior descending or left circumflex coronary artery oc•
clusion in dogs (their Table I), one becomes aware of dis•
crepancies or difficulties in individually applying the general 
correlations. For example, in Dog 7, the preferred function 
analysis B yielded 73% extent of dysfunction in the papillary 
short-axis cross section of the left ventricle, which corre•
sponded well with the 80% extent of the risk zone deter•
mined with contrast echo techniques. Yet, method B shows 
zero dysfunction for the high papillary section while contrast 
echocardiography yields a 33.6% perfusion defect. Thus, 
there is substantial variability, some of which may be at•
tributed to the method of contrast delineation. More exten•
sive comparisons should certainly be compiled in the closed 
chest model, rather than in open chest animals. There remain 
serious questions about the clinical application of myo•
cardial echo contrast delineation in the more common apical 
cross-sectional images of the left ventricle, and about the 
use of the technique in the presence of significant echo 
dropouts or poor quality of endocardial/epicardial interface 
definition. Finally, as has been pointed out by Kondo et a1. 
(13) and Ten Cate et al. (14), it is necessary to bear in mind 
the effects of contrast agent administration on the heart. 
Since gaseous bubbles are needed in echo contrast methods, 
it is appropriate to require more information on the safety 
of intracoronary. aortic root or coronary venous injections. 
As revealed in a study by Ten Cate et al. (15), transpul•
monary echo contrast studies of myocardium currently ap•
pear far from practicable. 
Contrast echo computerization has been applied to ana•
lyze the dynamics of myocardial echo contrast appearance 
and disappearance (9,16) from which one can derive indexes 
such as "washout," which seem to correlate with coronary 
blood flow (14). If further developed and corroborated, a 
quantitative myocardial contrast echo methodology could 
be a useful tool in evaluating ischemic states and interven•
tions affecting myocardial perfusion as well as cardiac func•
tion. Again, the clinical importance and potential of the 
technique are not yet clear. 
Future improvements in contrast agents. Fundamental 
to all quantitative echocardiographic contrast methods is the 
use of quality-controlled microbubbles and well character•
ized contrast solutions. At this time, and in spite of several 
reports (17,18), no fully satisfactory echo contrast agent is 
available for myocardial perfusion studies. To assure safety, 
minimize measurement artifacts and approach characteristic 
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myocardial transit times, such an agent should have neg•
ligible myocardial effects and feature highly uniform and 
echogenic microbubbles that could readily pass through the 
microcirculation (18). In addition, there is as yet no satis•
factory method of intravenous or right heart contrast admin•
istration for the quantitation of myocardial contrast echoes. 
The primary goal thus remains to develop echo contrast 
agents with sufficiently persistent highly uniform micro•
bubbles of a diameter of 3 to 5 /-L and capable of easy transit 
through the microcirculation. Among other complicating 
factors to be kept in mind is the major coronary hyperemia 
caused by certain agents (13), and a potentially unsatisfac•
tory intensity of myocardial echo contrast enhancement when 
microbubbles are extremely small. 
Future clinical applications. In spite of these words of 
caution and the evident challenges to be overcome, myo•
cardial contrast two-dimensional echocardiography remains 
a highly desirable and apparently achievable technique. The 
relatively simple method reported in this issue of the Journal 
clearly indicates that a potential already exists for the useful 
application to study' 'risk areas." Aortic root and also coro•
nary venous echo contrast injections (19) represent short•
term solutions in anticipation of a more generally applicable 
right-sided or intravenous administration. Among new ob•
servations, a significant normal state phasic alteration in 
myocardial echo contrast intensity occurs during the cardiac 
cycle, and this effect might be applied to differentiate a state 
of ischemia during which this phasic intensity change is 
greatly reduced or eliminated. 
We can expect selective application of myocardial con•
trast echocardiography in clinical studies, but clinical ob•
servations should be viewed with caution, particularly when 
the data involve insufficiently characterized agents or con•
trast agents with unspecified gas bubbles. Clinical reports 
should be examined in light of the potential problems I have 
indicated, particularly the limited or imperfect two-dimen•
sional echocardiographic cross-sectional images and effects 
of contrast administration. A potential area of interest relates 
to myocardial echo contrast intensities after coronary oc•
clusion and during the early reperfusion period. Contrast 
echocardiographic measurements of the ischemic zone as 
well as analysis of myocardial contrast washout might prove 
helpful in evaluating the effectiveness of the various acute 
reperfusion techniques that are receiving increasing attention. 
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